Botanix Pharmaceuticals (ASX:BOT) said it has amended its active pharmaceutical ingredient (API) supply agreement with Kaken Pharmaceutical, rescheduling purchases to December 2027 and December 2028 from the previously set dates for April 2026 and January 2027, according to a Monday Australian bourse filing.

The company said following a recent API purchase earlier this month, no further API purchases are required before December 2027, while activities continue to establish an alternate API supplier for Sofpironium Bromide with a view to de-risking the supply chain and achieving potential savings of 25% to 40% in cost of goods sold.

Deferring the purchases, in conjunction with proceeds from the current capital raise if approved, is expected to strengthen Botanix's ability to pursue its plans for Sofdra and its fulfillment platform, the filing added.

The company's shares fell 2% in recent Monday trade.